phenofAST solution provides AST ( antibiotic susceptibility test) in 4 hours, for a wide range of indications, in a cost effective way, using a physics based technology analyzer.
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
MindUP Invests in its 14th Portfolio Company: phenofAST
#Partners
About
Every 10 min, someone dies due to antibiotic resistant (AMR) bacteria infection, 50% of patients receive wrong antibiotic treatment for their infection while admitting to the hospital, and It takes 2-3 days for hospital lab test to find which antibiotic kills the bacteria. phenofAST has developed a fast and affordable clinical diagnostic solution for antibiotic susceptibility testing, providing definitive test results within 4 hours from a positive culture. Antibiotic susceptibility tests (AST) can take 2 to 3 days to produce definitive results, and with the accelerated spread of antibiotic-resistant bacteria, inappropriate antibiotic treatment results in mortality, morbidity, and higher healthcare costs across all stakeholders. phenofAST is the only company to have completely new & innovative physics-based technology, detecting cell division through laser light interferences, powered by AI analysis. phenofASTs solution provides same day AST test results in a cost effective way for a wide range of indications. This solution is applicable to any microbiology lab due to it's modular design – fit any lab space and needs, Green, minimal waste operation and low price of disposable testing cassette. With phenofAST solution, the microbiology lab will be able to provide the physician with the AST results, enabling the physician to adjust the antibiotic treatment on the same day that the patient was admitted, minimizing AMR ( antimicrobial resistance) and maximizing the right and effective treatment needed. Clinical validations done so far provided very high agreement with the gold standard. phenofAST goal is to become the Standard of Practice in antibiotic susceptibility testing, proving fast, cost-effective and wide-range solution for healthcare providers and payers.